MindWalk Holdings Corp.

NASDAQ:HYFT

Biotechnology

Healthcare
$1.08 +0.33%

+$0.01 today

Market cap
$50.88M
Beta
0.82
P/E (TTM)
-8.1
EPS (TTM)
-$0.26
52W Low $0.82High $3.25

Volume 0.20M

Average 0.32M

HYFT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

MindWalk Holdings Corp.NASDAQ: HYFT

EBITDA · Q3 FY2026 · quarter ended Jan 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -CA$3.67M, compared with -CA$22.97M a year earlier. Trailing-twelve-month EBITDA was -CA$10.88M.

Context

  • EBITDA amounted to 117.7% of revenue in FY2025, up 24.1 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -CA$8.9M (+69.2%) for the fiscal year ending Apr 2026, a step up from the -25.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
-CA$3.67M-22.9% QoQ
Last fiscal yearApr 2025
-CA$28.86M-25.7% YoY
LTMJan 2026
-CA$10.88M+76.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.0%-128.1%-212.1 pp
1 year-25.7%+69.2%+94.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
(28.86M) CAD
Year-over-year change
-25.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HYFT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +76.6% is the 2nd highest of 9, against a peer median of -9.8%.
  • EBITDA amounts to 59.3% of revenue for HYFT, versus a peer median of 11560.2%.
HYFT Competitors
EBITDA for HYFT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$148.02M USD+264.5%—223.7%
BYSIBeyondSpring Inc.LTM Mar 2026-$8.02M USD-9.0%——
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$10.88M CAD+76.6%—59.3%
CLNNClene Inc.LTM Mar 2026-$29.2M USD-21.6%—21792.5%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M USD-164.0%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$52.24M USD-1.2%—1327.8%
ATYRaTyr Pharma, Inc.LTM Mar 2026-$68.69M USD-10.6%—36154.2%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$86.7M USD+32.0%——
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M USD-21.2%——
Peer median (excluding HYFT) —-9.8%—11560.2%

Competitors are the stored peer set for HYFT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue17.91M19.36M20.67M24.52M24.52M
Cost of Revenue6.37M8.38M9.1M12.47M10.97M
Gross Profit11.54M10.98M11.56M12.05M13.55M
Gross Margin64.4%56.7%56.0%49.2%55.3%
Research & Development1.97M7.66M14.1M4.04M4.94M
Selling, General & Admin13.27M18.06M18.99M19.14M19.03M
Operating Expenses15.71M27.66M37.17M25.82M25.74M
Depreciation & Amortization3.71M3.77M6.69M5.74M5.12M
EBITDA(1.42M)(11.99M)(21.04M)(22.95M)(28.86M)
EBITDA Margin-7.9%-61.9%-101.8%-93.6%-117.7%
Operating Income(4.18M)(16.67M)(25.61M)(13.76M)(12.2M)
Operating Margin-23.3%-86.1%-123.9%-56.1%-49.7%
Interest Income265.01K279K122K23K0
Interest Expense602.37K85K30K19K9.91K
Other Income / Expenses(1.82M)825K(2.14M)(14.94M)(22.07M)
Income Before Tax(6M)(15.85M)(27.75M)(28.7M)(34.27M)
Pre-Tax Margin-33.5%-81.8%-134.3%-117.1%-139.8%
Income Tax Expense1.35M861K(1.19M)(2.59M)(4.03M)
Net Income(7.34M)(16.71M)(26.56M)(26.12M)(30.23M)
Net Margin-41.0%-86.3%-128.5%-106.5%-123.3%
EPS (Basic)(0.45)(0.87)(1.07)(1.03)(0.90)
EPS (Diluted)(0.45)(0.87)(1.07)(1.03)(0.90)
Weighted Avg Shares16.47M19.69M24.9M25.64M33.39M
Weighted Avg Shares (Diluted)16.47M19.69M24.9M25.64M33.39M

MindWalk Holdings Corp.

NASDAQ:HYFT

Intrinsic Alpha fair value

Locked

Current Price

$1.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.